Compare XPEL & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPEL | HROW |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2019 | 2008 |
| Metric | XPEL | HROW |
|---|---|---|
| Price | $38.07 | $27.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $57.00 | ★ $63.00 |
| AVG Volume (30 Days) | 251.8K | ★ 544.1K |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.12 | ★ 71.43 |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $476,200,000.00 | N/A |
| Revenue This Year | $11.71 | $28.41 |
| Revenue Next Year | $10.64 | $58.14 |
| P/E Ratio | $23.75 | ★ N/A |
| Revenue Growth | ★ 13.27 | N/A |
| 52 Week Low | $36.99 | $25.76 |
| 52 Week High | $55.91 | $54.98 |
| Indicator | XPEL | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 28.90 | 41.61 |
| Support Level | $36.99 | $26.96 |
| Resistance Level | $46.97 | $30.28 |
| Average True Range (ATR) | 2.12 | 1.31 |
| MACD | -0.56 | 0.07 |
| Stochastic Oscillator | 0.28 | 41.37 |
XPEL Inc is a supplier of protective films, coatings, and related services principally to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from Product, which includes Paint protection film and Window film. The company derives revenue from Service, which includes Software, Cutbank credits, and Installation labor. The majority of revenue is derived from the United States.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.